Your browser doesn't support javascript.
loading
Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study.
Livne-Margolin, Moran; Ling, Daniel; Attia-Konyo, Shani; Abitbol, Chaya Mushka; Haj-Natour, Ola; Ungar, Bella; Ben-Horin, Shomron; Kopylov, Uri.
Afiliación
  • Livne-Margolin M; Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: Moran.livnemargolin@sheba.health.gov.il.
  • Ling D; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Attia-Konyo S; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Internal Medicine E, Chaim Sheba Medical Center, Tel Hashomer, Israel.
  • Abitbol CM; Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
  • Haj-Natour O; Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
  • Ungar B; Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Ben-Horin S; Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Kopylov U; Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Dig Liver Dis ; 55(2): 223-229, 2023 02.
Article en En | MEDLINE | ID: mdl-36241535
INTRODUCTION: Extraintestinal manifestations (EIM) are associated with diminished quality of life. The efficacy of Ustekinumab and vedolizumab for EIM treatment is not well established. The aim was to compare the effectiveness of ustekinumab and vedolizumab for treatment of EIM in IBD. METHODS: We included IBD patients treated with vedolizumab or ustekinumab in the Gastroenterology department, Sheba Medical Center, for up to 52 weeks between 2015 and 2021. Patients with active EIM before treatment initiation were included. RESULTS: 111 patients were included. 53 patients (48%) were treated with ustekinumab; 88% (n-99) had CD. The most common EIM was arthralgia (95/111, 84%). Patients treated with ustekinumab were more likely to be anti-TNF experienced (n-51/53 [96%] compared with vedolizumab n = 36/58 [62%], p < 0.001). Clinical response of EIM at week 52 was achieved in 36% of patients treated with ustekinumab (n-18/50) and 34% of patients (n-19/54) treated with vedolizumab, with no statistically significant difference (p = 0.9). No statistical significance was achieved for patients presented with arthralgia. Clinical response of arthralgia at week 52 was seen in 34% (n-19/55) and 36% (n-18/46) of the patients treated with vedolizumab and ustekinumab, respectively, (p = 0.3). CONCLUSION: In this study, no difference was found between vedolizumab and ustekinumab regarding their effect on EIM in IBD patients for up to 52 weeks.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Enfermedad de Crohn Tipo de estudio: Observational_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Dig Liver Dis Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Enfermedad de Crohn Tipo de estudio: Observational_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Dig Liver Dis Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article Pais de publicación: Países Bajos